

Neuren presents at annual International Meeting for Autism Research

Melbourne, Australia, 21 May 2014: Neuren Pharmaceuticals (ASX: NEU) presented the attached poster at the International Meeting for Autism Research (IMFAR) in Atlanta on 15 May 2014. The poster describes the development of a Clinical Global Impression Scale (CGI) with measures specific to the signs and symptoms of Rett Syndrome. The CGI, which measures severity of illness and improvement in illness, is being used as one of several indicators of clinical efficacy in Neuren's Phase 2 clinical trial of NNZ-2566 in Rett Syndrome. The trial is the first commercial multi-site clinical trial in Rett Syndrome.

To date 51 subjects have been enrolled in the trial. Neuren expects to complete enrolment in June 2014 and announce top-line results from the trial in the fourth quarter of 2014.

About Rett Syndrome

Rett Syndrome is a post-natal neurological disorder that occurs almost exclusively in females following apparently normal development for the first six months of life. Typically, between 6 to 18 months of age, patients experience a period of rapid decline with loss of purposeful hand use and spoken communication. Many patients have recurrent seizures. They experience a variety of motor problems including increased muscle tone (spasticity) and abnormal movements. These individuals are never able to provide for their own needs. It is a rare disorder and is believed to be second only to Down Syndrome as a genetically-determined cause of chronic neurological problems in females that include severe communication, motor disabilities and epilepsy. Rett Syndrome is caused by mutations on the X chromosome on a gene called MECP2. There are more than 200 different mutations found on the MECP2 gene. Rett Syndrome strikes all racial and ethnic groups and occurs worldwide in approximately 1 in every 10,000 live female births.

About NNZ-2566

NNZ-2566 is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, NNZ-2566 exhibits a wide range of important effects including inhibiting neuroinflammation, normalising the role of microglia and correcting deficits in synaptic function. In the Fragile X model, these actions resulted in statistically significant improvement in all core anatomic and behavioural features of the disorder that were assessed. NNZ-2566 is being developed both in intravenous and oral formulations for a range of acute and chronic conditions. The intravenous form of NNZ-2566 is presently in a Phase 2 clinical trial in patients with moderate to severe traumatic brain injury. The oral form of NNZ-2566 is in Phase 2 trials in Rett Syndrome and Fragile X Syndrome. All three programs have received Fast Track designation from the US FDA and the Fragile X Syndrome program has also received Orphan Drug designation. Neuren intends to implement a Phase 2 clinical trial with the oral form of NNZ-2566 in patients with concussion (mild traumatic brain injury).

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a publicly listed biopharmaceutical company focusing on the development of new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions such as Rett Syndrome and Fragile X Syndrome as well as acute neurological injuries. Neuren presently has a clinical stage molecule, NNZ-2566 in three Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

For more information, please contact:

Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com +61 417 520 509